Panjon Ltd
Incorporated in 1983, Panjon Ltd manufactures and trades consumer and pharmaceutical products
- Market Cap ₹ 37.0 Cr.
- Current Price ₹ 21.6
- High / Low ₹ 25.0 / 15.7
- Stock P/E 103
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 0.17 %
- ROE 2.22 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Promoter holding has increased by 2.28% over last quarter.
Cons
- Company has high debtors of 262 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | |
|---|---|---|
| 19.47 | 12.23 | |
| 24.09 | 12.49 | |
| Operating Profit | -4.62 | -0.26 |
| OPM % | -23.73% | -2.13% |
| 0.04 | 0.43 | |
| Interest | 0.00 | 0.00 |
| Depreciation | 0.13 | 0.14 |
| Profit before tax | -4.71 | 0.03 |
| Tax % | -27.18% | -1,133.33% |
| -3.43 | 0.36 | |
| EPS in Rs | -2.21 | 0.23 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 35% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | |
|---|---|---|
| Equity Capital | 15.50 | 15.50 |
| Reserves | 0.52 | 0.89 |
| 1.52 | 1.41 | |
| 0.51 | 0.25 | |
| Total Liabilities | 18.05 | 18.05 |
| 0.92 | 0.84 | |
| CWIP | 0.00 | 0.00 |
| Investments | 1.08 | 1.09 |
| 16.05 | 16.12 | |
| Total Assets | 18.05 | 18.05 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | |
|---|---|---|
| 0.89 | -0.20 | |
| 4.74 | -0.06 | |
| -5.14 | -0.19 | |
| Net Cash Flow | 0.49 | -0.44 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | |
|---|---|---|
| Debtor Days | 184.28 | 262.04 |
| Inventory Days | 46.16 | 104.69 |
| Days Payable | 7.20 | 4.27 |
| Cash Conversion Cycle | 223.24 | 362.46 |
| Working Capital Days | 263.39 | 430.36 |
| ROCE % | 0.17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - ENCLOSED HEREWITH THE NEWSPAPER ADVERTISEMENT CLIPPINGS FOR THE QUARTER ENDED 30/09/2024
-
Board Meeting Outcome for BOARD MEETING OUTCOME DATED 14/11/2024
14 Nov - Board meeting outcome and unaudited financial results.
- UNAUDITED FINANCIAL RESULT FOR THE QUARTER & HALF YEAR ENDED 30Th SEPTEMBER, 2024 14 Nov
-
Board Meeting Intimation for MEETING OF Board HELD ON 14Th NOVEMBER, 2024 AT 4 PM
7 Nov - Board meeting scheduled for financial results approval.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Oct - ENCLOSED HEREWITH COMPLIANCE CERTIFIATE UNDER REGULATION 74(5) FOR THE QUARTER ENDED 30TH SEPTEMBER, 2024
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2007
from bse
Product Profile:[1][2]
Panjon Tablet, Panjon Balm, Panjon Cough Syrup, Panjon Cough Drops, Panjon Inhaler, Hinkargiri Hair Oil, Kery, Percy, Swad, Swad Awla, Swad Khajoor, Swad Chatpati, Swad Shoppee, Swad Energy Drink, Panjon Dental Cream, Purti Mouth Freshner
Distribution Network:[3]
Company markets and manufactures its products and undertakes contract manufacturing for MNCs. Company sells its formulations under own brand name, through a nationwide marketing network of 20+ states through a chain of 80 distributors who in turn sell goods to 1000 appointed stockiest and 4,50,000 retailers, with help of a field force of 300+ sales representatives